

IN THE CLAIMS

Please rewrite Claims 106, 110, 111, 112, 114 and 115 in their entirety as follows (the changes on this page from the previous version to the rewritten version are shown in Appendix B, with brackets for deleted matter and underlines for added matter). (Appendix C, a list of all claims filed in connection with this application, sets forth the status of claims 106-142):

Claims

Sub F1

E3

106. (Amended) A method of introducing protein in a mammal which comprises delivering to a blood vessel in the mammal a transfected vascular cell, the transfected cell originating from the mammal and comprising an exogenous nucleic acid encoding the protein and competent to express the protein when implanted in the mammal.

110. (Amended) The method of claim 106 wherein the recombinant protein is competent to induce angiogenesis.

E4

111. (Amended) The method of claim 106, wherein the recombinant protein is competent to induce revascularization.

112. (Amended) The method of claim 106 wherein the protein is useful in the treatment of an ischemic organ.

114. (Amended) The method of claim 106 wherein the protein is competent to improve the vascular or cerebrovascular circulation.

G5
Sub F2

115. (Amended) A method of treating a human patient comprising the step of site-specific instillation of cells into the patient, wherein the cells originate from the patient and are selected from the group consisting of endothelium, smooth muscle, and parenchymal cells.